



News Release

For immediate release

September 22, 2016

Blis Technologies Wins Two Awards in Deloitte Fast 50

NZX-listed Blis Technologies Limited last night received two Otago Southland awards in the Deloitte Fast 50 at an event in Dunedin last night. Fast 50 takes place in 32 countries around the world, and the Deloitte Fast 50 ranks and celebrates fast-growing companies.

Blis won the awards for Fastest Growing Exporter and Fastest Growing Mature Business and was confirmed as one of the national Fast 50 companies.

CEO Brian Watson said the awards were due to a lot of hard work from a lot of people.

“We have been focusing on improving systems, concentrating effort in specific offshore markets and developing a solid strategy especially related to our finished goods. It takes time and teamwork and these awards help remind us that the work we are doing creates results.”

In the last three years Blis has grown revenue by over 100 percent each year, going from a turnover of \$NZ1.3 million in FY2014 to a \$NZ5.6 million in FY2016.

“Our guidance to the market for FY2017 is for a trading revenue in excess of \$NZ8 million and to deliver a net profit before tax in excess of \$0.7m.”

Blis Technologies was formed in 2001 to commercialise probiotic bacteria with bacteriocin activity – essentially a natural antibiotic to control streptococcal throat infections. Probiotics for the oral cavity are unique in their action and as such the Blis range of probiotics are the world’s first in this space.

“Since entering the market, we have developed a number consumer products under our own brand and also have a new product development stream in action.”

Export markets continue to be opened up through regulatory approvals. During 2015 approval for substantial and specific claims was achieved in Canada for products containing BLIS K12 with the issuance of a US Food and Drug Administration ‘Letter of No Objection’ more commonly known as GRAS or ‘Generally Recognized As Safe’.

“This added a new level of credibility for Blis and has the potential to put the conversations with larger consumer food and beverage companies in the US on a stronger footing.”

The underlying science behind Blis products is backed by over 30 clinical trials.

END

For further comment contact:

Brian Watson

For media assistance contact:

Shar Carlini

021 509 905